

# Department of Health and Human Services Palliative Care Clinical Network

## Disclaimer for endorsed documents

This clinical guidance document (the document) has been endorsed in the state of Victoria, Australia to promote and facilitate standardisation and consistency in palliative care practice using a multidisciplinary approach.

Information in the document is current at the time of publication. The Department of Health and Human Services - Palliative Care Clinical Network (PCCN) does not accept liability for any person for loss or damage incurred as a result of reliance upon the material contained in this document. Clinical material offered in this document does not replace or remove independent professional advice, clinical judgement or the professional care and duty necessary for each specific clinical case. Clinical care carried out in accordance with this document should be provided within the context of locally available resources and expertise.

This document does not address all elements of standard practice and assumes that individual clinicians:

- discuss care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes the use of interpreter services where necessary;
- advise consumers of their choice and ensure informed consent is obtained;
- provide care within their scope of practice, meet all legislative requirements and maintain standards of professional conduct;
- apply standard precautions and additional precautions as necessary, when delivering care;
- document care in accordance with local and mandatory requirements.

Once printed the currency of this document is limited.

April 2015



Eastern Metropolitan Region  
Palliative Care Consortium

---

**Eastern Metropolitan Region Palliative Care Consortium (Victoria)**

**Clinical Group**

# **Syringe Driver Drug Compatibilities – Guide to Practice 2013**

July 2013

Updated as Version 2 – November 2014

These guidelines have been copyrighted. The Eastern Metropolitan Region Palliative Care Consortium (EMRPCC) grants permission to reproduce parts of this publication for clinical and educational use only, provided that the EMRPCC is acknowledged. Requests to reproduce this document, for purposes other than those stated above, should be addressed to:

Consortium Manager  
Eastern Metropolitan Region Palliative Care Consortium  
c/- PO Box 2110  
Rangeview 3132  
Victoria  
Australia  
or  
[consortiummanager@epc.asn.au](mailto:consortiummanager@epc.asn.au)

## INSTRUCTIONS FOR USE

These guidelines work best if used electronically. The Contents have hyperlinks to each section.  
Printing: It is highly recommended these guidelines are printed in colour, to aid ease of use.

### Contents

<b>INSTRUCTIONS FOR USE</b> .....	<b>2</b>
<b>DISCLAIMER</b> .....	<b>3</b>
<b>KEY</b> .....	<b>3</b>
<b>Instructions for reading the list of drugs..</b> .....	<b>3</b>
<b>Compatibility</b> .....	<b>3</b>
<b>Infusion site problems (note C)</b> .....	<b>4</b>
<b>Diluent information</b> .....	<b>4</b>
<b>Atropine</b> .....	<b>5</b>
<b>Clonazepam</b> .....	<b>5</b>
<b>Cyclizine</b> .....	<b>6</b>
<b>Fentanyl</b> .....	<b>8</b>
<b>Glycopyrrolate</b> .....	<b>9</b>
<b>Haloperidol</b> .....	<b>10</b>
<b>Hydromorphone</b> .....	<b>12</b>
<b>Hyoscine Butylbromide (Hyoscine BBr)</b> .....	<b>13</b>
<b>Hyoscine Hydrobromide (Hyoscine HBr)</b> .....	<b>14</b>
<b>Ketamine</b> .....	<b>15</b>
<b>Ketorolac</b> .....	<b>16</b>
<b>Levomepromazine</b> .....	<b>16</b>
<b>Lignocaine</b> .....	<b>17</b>
<b>Methadone</b> .....	<b>17</b>
<b>Metoclopramide</b> .....	<b>17</b>
<b>Midazolam</b> .....	<b>18</b>
<b>Morphine Sulfate</b> .....	<b>19</b>
<b>Octreotide</b> .....	<b>19</b>
<b>Olanzapine</b> .....	<b>19</b>
<b>Ondansetron</b> .....	<b>19</b>
<b>Oxycodone</b> .....	<b>20</b>
<b>Ranitidine</b> .....	<b>20</b>
<b>Sufentanil</b> .....	<b>20</b>
<b>REFERENCES</b> .....	<b>21</b>
<b>Acknowledgements</b> .....	<b>21</b>

## DISCLAIMER

The information in this document is intended as a **guide** only. It is the responsibility of the user to ensure information is used correctly. This guide reflects Victorian palliative care practice and published evidence at the time of review.

All drug compatibility combinations derived from this guide should be checked and prescribed by a medical doctor or nurse practitioner with appropriate experience before administering. If you require further information regarding drug combinations and compatibility data, contact a specialist hospital-based pharmacy drug information service.

Caution should be used when combining drugs in syringe drivers; mixtures should be closely monitored for discolouration, precipitation and crystallisation.

Drug doses should be modified in response to the patient/client's clinical situation and status, including previous exposure to opioids and concurrent medications. All patients should be monitored closely when commencing and/or switching opioid medications.

In accordance with quality practice, this guide should be submitted for organisational approval prior to use. When setting up and using syringe drivers, follow your organisation's policy and procedures.

### KEY

#### Instructions for reading the list of drugs

All drugs are listed in alphabetical order. When searching for drug combinations, search by the drug which occurs first alphabetically. Drug combinations *are not* repeated in reverse order

Example: Haloperidol  
 Haloperidol, Hydromorphone  
 Haloperidol, Hydromorphone, Metoclopramide

Symbol	Explanation
	Compatible, observational data from clinical setting
	Compatible, read note for explanation
	Conflicting information regarding compatibility – proceed with caution
	Incompatible
NaCl 0.9%	Diluent = Sodium Chloride 0.9% (NaCl 0.9%)
WFI	Diluent = Water For Injection (WFI)
NaCl 0.9%      WFI	Diluent = Sodium Chloride 0.9% (NaCl 0.9%) or Water for Injection (WFI)

<b>NOTE A</b>	Chemically compatible in tests
<b>NOTE B</b>	Physically compatible in tests
<b>NOTE C</b>	Potential for site reaction – see 'Infusion Site Problems'

### Compatibility

Information gathered from the clinical setting is the observation for any physical changes, as well as clinical assessment. This is documented as *compatible, observational data from clinical setting* and is marked with a green tick



### Chemical compatibility (note A)

Chemical compatibility data is obtained by laboratory analysis the drug combination in the range of combinations usually used, in the usual diluent and over a range of temperatures.

### Physical compatibility (note B)

Physical compatibility data can also be obtained by laboratory analysis. The lack of physical change such as discoloration, clouding or crystallization is tested microscopically.

Compatibility can be dependent on the concentration of each drug in the total final volume being infused, rather than the actual dose.

Numerous factors effect stability and compatibility including drug salt, strength, diluents, order of drawing up, temperature and infusion periods. Seek specialist palliative care or pharmacist advice when needed.

Monitoring of the combined drugs in the syringe driver throughout the infusion period is advised.

When combining medications for syringe driver use, be aware compatibility data is available for only a few drug combinations. As a consequence, some combinations are not listed in this guide.

### It is recommended that the number of medications in one syringe driver be limited to three.

If several medications are required, consider using more than one syringe driver where this is practical. The more medications that are mixed in one syringe, the higher the potential for interaction, particularly where pH differs.

If the combination is not listed in this practice guideline, consult

1. Dickman A, Schneider J. The Syringe Driver Continuous subcutaneous infusions in palliative care. 3rd ed. Oxford: Oxford University Press; 2011 (1)
2. The syringe driver database on the palliative care website [www.palliativesdrugs.com](http://www.palliativesdrugs.com) (2)

For further information see Guidelines for Subcutaneous Infusion Device Management in Palliative Care – second edition 2010 available at [www.health.qld.gov.au/cpcrc](http://www.health.qld.gov.au/cpcrc) (3)

### Infusion site problems (note C)

A plastic (Teflon® or Vialon®) cannula should be used rather than a metal butterfly needle to reduce site inflammation. A skin reaction at the infusion site is most commonly found with **cyclizine, ketamine, levomepromazine and methadone**. Excluding mixtures containing cyclizine, sodium chloride 0.9% can be used as the diluent in an attempt to reduce site reactions with irritant infusions. Sites may last up to a week, depending on the drugs used. The site should be changed if painful or inflamed. Routine rotation to a different subcutaneous site every 72 hours reduces the frequency of site problems. If frequent resiting is necessary, e.g. every 24 to 48 hours, consider the following strategies:

- Use a larger syringe to enable a more dilute mixture to be used, thereby decreasing the final drug concentrations
- Change to a 12 hourly regimen, thereby permitting further dilution of the drugs
- Change an irritant drug to a less irritant alternative
- Inject dexamethasone 1mg directly into the infusion site, via the cannula to be used. Flush with NaCl 0.9% then connect the syringe driver and commence.(1)

### Chlorpromazine, diazepam and prochlorperazine

These drugs are not recommended to be given by subcutaneous infusion due to severe local reactions. (3)

### Phenobarbitone

Phenobarbitone has an alkaline pH and can cause tissue necrosis when administered as subcutaneous bolus injection. In practice, phenobarbitone can be initiated with a bolus intramuscular or intravenous injection, then via subcutaneous infusion with NaCl 0.9% or WFI as diluent. It should be given via a separate syringe driver. Seek specialist advice. (1)

### Diluent information

Sodium Chloride 0.9% (NaCl 0.9%) and Water for Injection (WFI) are suitable for subcutaneous infusions. Diluting syringe contents as much as possible is recommended to reduce site irritation.

NaCl 0.9% is recommended as the diluent of choice when drugs are compatible with more than one solution. It is closest to physiological tonicity, therefore less likely to cause irritation. The main exception to this is **cyclizine** which should always be diluted in **WFI**.

Glucose 5% was included in the 2008 document. It is not used in the Victorian setting and is no longer included in this guide





## Syringe Driver Drug Compatibilities – Guide to Practice 2013

DRUG	COMPATIBILITY	DILUENT	COMMENT	REFERENCE	
<b>Atropine</b>		NaCl 0.9%	Atropine may be administered via continuous subcutaneous infusion, but is not commonly used in Australia. Information on compatibility with other drugs is limited therefore not recommended	5	
<b>Clonazepam</b>		NaCl 0.9%	WFI	There is a significant loss when infused through PVC tubing which can be addressed by using non PVC tubing or titrating the dose to desired effect	1
Clonazepam, Glycopyrrolate, Oxycodone		NaCl 0.9%		2	
Clonazepam, Haloperidol, Methadone	C	NaCl 0.9%		1	
Clonazepam, Haloperidol, Morphine Sulfate		NaCl 0.9%	WFI	2	
Clonazepam, Haloperidol, Morphine Tartrate		NaCl 0.9%		1	
Clonazepam, Haloperidol, Oxycodone	B	NaCl 0.9%	WFI	1	
Clonazepam, Hydromorphone		NaCl 0.9%		2	
Clonazepam, Hyoscine Butylbromide		NaCl 0.9%	WFI	2	
Clonazepam, Hyoscine Butylbromide, Morphine Sulfate		NaCl 0.9%		1	
Clonazepam, Hyoscine Butylbromide, Oxycodone	B	NaCl 0.9%	WFI	1	
Clonazepam, Hyoscine Hydrobromide, Oxycodone	B	NaCl 0.9%	WFI	1	
Clonazepam, Ketamine, Morphine Tartrate	C	NaCl 0.9%		1	
Clonazepam, Ketamine, Oxycodone	C	NaCl 0.9%		2	
Clonazepam, Levomepromazine, Morphine Sulfate	C	NaCl 0.9%	WFI	1	
Clonazepam, Levomepromazine, Oxycodone	C	NaCl 0.9%	WFI	1	





## Syringe Driver Drug Compatibilities – Guide to Practice 2013














DRUG	COMPATIBILITY	DILUENT	COMMENT	REFERENCE
Clonazepam, Methadone	C	NaCl 0.9%		1
Clonazepam, Metoclopramide, Oxycodone	C	NaCl 0.9%		1
Clonazepam, Morphine Sulfate	C	NaCl 0.9%   WFI		1,2
Clonazepam, Octreotide, Oxycodone	C	NaCl 0.9%		1
Clonazepam, Oxycodone	B	NaCl 0.9%   WFI		1
<b>Cyclizine</b>	C	WFI	Cyclizine may precipitate as the concentration of chloride ions increases(e.g. with metoclopramide or oxycodone) or if the pH is greater than 6.8	1
Cyclizine, Glycopyrrolate, Haloperidol	C	WFI		2
Cyclizine, Glycopyrrolate, Oxycodone	C	WFI	Cyclizine may precipitate as the concentration of chloride ions increases(e.g. with metoclopramide or oxycodone) or if the pH is greater than 6.8	1
Cyclizine, Haloperidol	C	WFI		1
Cyclizine, Haloperidol, Hyoscine Butylbromide				2
Cyclizine, Haloperidol, Metoclopramide	C	WFI	Cyclizine may precipitate as the concentration of chloride ions increases(e.g. with metoclopramide or oxycodone) or if the pH is greater than 6.8	2
Cyclizine, Haloperidol, Midazolam	C	WFI		1
Cyclizine, Haloperidol, Morphine Sulfate	A,B,C	WFI		1
Cyclizine, Haloperidol, Octreotide	C	WFI		2
Cyclizine, Haloperidol, Oxycodone	A,B,C	WFI	Cyclizine may precipitate as the concentration of chloride ions increases(e.g. with metoclopramide or oxycodone) or if the pH is greater than 6.8	1
Cyclizine, Hydromorphone	C	WFI		2







## Syringe Driver Drug Compatibilities – Guide to Practice 2013

DRUG	COMPATIBILITY	DILUENT	COMMENT	REFERENCE
Cyclizine, Hydromorphone, Octreotide	 C	WFI		1
Cyclizine, Hyoscine Butylbromide	 C	WFI		2
Cyclizine, Hyoscine Butylbromide, Morphine Sulfate	 C	WFI		1
Cyclizine, Hyoscine Butylbromide, Oxycodone				2
Cyclizine, Hyoscine Hydrobromide, Midazolam	 C	WFI		2
Cyclizine, Hyoscine Hydrobromide, Morphine Sulfate	 C	WFI		2
Cyclizine, Hyoscine Hydrobromide, Morphine Tartrate	 C	WFI		1
Cyclizine, Levomepromazine	 C	WFI	Cyclizine and levomepromazine are generally not administered together due to an increased risk of adverse effects	1,2
Cyclizine, Levomepromazine, Morphine Sulfate	 C	WFI	Cyclizine and levomepromazine are generally not administered together due to an increased risk of adverse effects	1
Cyclizine, Levomepromazine, Octreotide	 C	WFI	Cyclizine and levomepromazine are generally not administered together due to an increased risk of adverse effects	1,2
Cyclizine, Levomepromazine, Oxycodone	 C	WFI	Cyclizine may precipitate as the concentration of chloride ions increases(e.g. with metoclopramide or oxycodone) Cyclizine and levomepromazine are generally not administered together due to an increased risk of adverse effects	1
Cyclizine, Methadone	 C	WFI		2
Cyclizine, Metoclopramide	 C	WFI	The prokinetic effect of metoclopramide may be inhibited by cyclizine.	1







## Syringe Driver Drug Compatibilities – Guide to Practice 2013

DRUG	COMPATIBILITY	DILUENT	COMMENT	REFERENCE
			Cyclizine may precipitate as the concentration of chloride ions increases(e.g. with metoclopramide or oxycodone)	
Cyclizine, Metoclopramide, Octreotide	C	WFI	The prokinetic effect of metoclopramide may be inhibited by cyclizine. Cyclizine may precipitate as the concentration of chloride ions increases(e.g. with metoclopramide or oxycodone)	1
Cyclizine, Midazolam	C	WFI		1
Cyclizine, Midazolam, Morphine Sulfate	A,B,C	WFI		1
Cyclizine, Midazolam, Oxycodone	A,B,C	WFI	Cyclizine may precipitate as the concentration of chloride ions increases(e.g. with metoclopramide or oxycodone)	1
Cyclizine, Morphine Sulfate	C	WFI		1
Cyclizine, Morphine Sulfate, Octreotide	C	WFI		2
Cyclizine, Morphine Tartrate	C	WFI		2
Cyclizine, Ondansetron, Oxycodone				2
Cyclizine, Oxycodone	A,B,C	WFI	Cyclizine may precipitate as the concentration of chloride ions increases(e.g. with metoclopramide or oxycodone)	1,6
<b>Fentanyl</b>		NaCl 0.9%      WFI	The volume of fentanyl injection may restrict its use in the syringe driver. A separate or 12 hourly syringe driver may be required.	1
Fentanyl, Haloperidol, Midazolam		NaCl 0.9%		1
Fentanyl, Hyoscine Butylbromide, Midazolam	A,B	NaCl 0.9%		1
Fentanyl, Ketamine	B,C	NaCl 0.9%		5,7
Fentanyl, Metoclopramide		WFI		2





## Syringe Driver Drug Compatibilities – Guide to Practice 2013

DRUG	COMPATIBILITY	DILUENT	COMMENT	REFERENCE
Fentanyl, Metoclopramide, Midazolam	A,B	NaCl 0.9%		1
Fentanyl, Midazolam	A,B	NaCl 0.9%		1
Fentanyl, Ondansetron	A,B	NaCl 0.9%		1
<b>Glycopyrrolate</b>		NaCl 0.9% <b>WFI</b>		1
Glycopyrrolate, Haloperidol, Ondansetron		NaCl 0.9%		1
Glycopyrrolate, Ketamine Oxycodone	C	NaCl 0.9%		2
Glycopyrrolate, Levomepromazine, Midazolam	C	NaCl 0.9%		1
Glycopyrrolate, Levomepromazine, Morphine Sulfate	C	NaCl 0.9%		1
Glycopyrrolate, Levomepromazine, Octreotide	C	NaCl 0.9% <b>WFI</b>		1
Glycopyrrolate, Levomepromazine, Oxycodone	C	NaCl 0.9% <b>WFI</b>		1
Glycopyrrolate, Methadone, Midazolam	C	NaCl 0.9%		1
Glycopyrrolate, Metoclopramide, Morphine Sulfate		NaCl 0.9%	The prokinetic effect of metoclopramide may be inhibited by glycopyrrolate.	1
Glycopyrrolate, Metoclopramide, Oxycodone		NaCl 0.9% <b>WFI</b>	The prokinetic effect of metoclopramide may be inhibited by glycopyrrolate	2
Glycopyrrolate, Midazolam		NaCl 0.9%		2
Glycopyrrolate, Midazolam, Morphine Sulfate		NaCl 0.9% <b>WFI</b>		1
Glycopyrrolate, Midazolam, Oxycodone		NaCl 0.9% <b>WFI</b>		1
Glycopyrrolate, Ondansetron	A,B	NaCl 0.9%		1





## Syringe Driver Drug Compatibilities – Guide to Practice 2013

DRUG	COMPATIBILITY	DILUENT	COMMENT	REFERENCE
Glycopyrrolate, Oxycodone		NaCl 0.9%    WFI		6
<b>Haloperidol</b>		NaCl 0.9%    WFI	At concentrations greater than 1mg/mL, haloperidol may precipitate in NaCl 0.9% Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity, eg haloperidol, metoclopramide and levomepromazine.	1
Haloperidol, Hydromorphone		NaCl 0.9%    WFI		1
Haloperidol, Hydromorphone, Ketamine		NaCl 0.9%    WFI		2
Haloperidol, Hydromorphone, Metoclopramide		NaCl 0.9%	Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity, e.g. haloperidol, metoclopramide and levomepromazine	2
Haloperidol, Hydromorphone, Midazolam		NaCl 0.9%    WFI		2
Haloperidol, Hydromorphone, Ranitidine		NaCl 0.9%		2
Haloperidol, Hyoscine Butylbromide		NaCl 0.9%		1
Haloperidol, Hyoscine Butylbromide Oxycodone		NaCl 0.9%    WFI		1
Haloperidol, Hyoscine Butylbromide, Metoclopramide		NaCl 0.9%	The prokinetic effect of metoclopramide may be inhibited by hyoscine butylbromide Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity eg haloperidol, metoclopramide and levomepromazine	2
Haloperidol, Hyoscine Butylbromide, Midazolam		NaCl 0.9%		1
Haloperidol, Hyoscine Butylbromide, Morphine Sulfate		NaCl 0.9%    WFI		1,2
Haloperidol, Hyoscine Butylbromide, Ranitidine		NaCl 0.9%		2
Haloperidol, Hyoscine Hydrobromide		NaCl 0.9%		8
Haloperidol, Hyoscine Hydrobromide, Morphine Sulfate		NaCl 0.9%		1





## Syringe Driver Drug Compatibilities – Guide to Practice 2013

DRUG	COMPATIBILITY	DILUENT	COMMENT	REFERENCE
Haloperidol, Hyoscine Hydrobromide, Octreotide		NaCl 0.9%		2
Haloperidol, Hyoscine Hydrobromide, Oxycodone	B	NaCl 0.9%    WFI		1
Haloperidol, Ketamine	C	NaCl 0.9%		1
Haloperidol, Ketamine, Midazolam	C	NaCl 0.9%    WFI		1,2
Haloperidol, Ketamine, Morphine Sulfate	C	NaCl 0.9%		1
Haloperidol, Ketamine, Oxycodone	B, C	NaCl 0.9%    WFI		1
Haloperidol, Levomepromazine, Morphine Sulfate	C	NaCl 0.9%    WFI	Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity e.g. haloperidol, metoclopramide and levomepromazine	2
Haloperidol, Metoclopramide	B	NaCl 0.9%	Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity, e.g. haloperidol, metoclopramide and levomepromazine	1
Haloperidol, Metoclopramide, Midazolam	B	NaCl 0.9%	Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity, e.g. haloperidol, metoclopramide and levomepromazine	1
Haloperidol, Metoclopramide, Morphine Sulfate		NaCl 0.9%    WFI	Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity, e.g. haloperidol, metoclopramide and levomepromazine	1,2
Haloperidol, Metoclopramide, Morphine Tartrate		NaCl 0.9%	Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity, e.g. haloperidol, metoclopramide and levomepromazine	2
Haloperidol, Metoclopramide, Octreotide		NaCl 0.9%	Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity, e.g. haloperidol, metoclopramide and levomepromazine	2
Haloperidol, Metoclopramide, Oxycodone		WFI	Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity, e.g. haloperidol, metoclopramide and levomepromazine	2
Haloperidol, Metoclopramide, Ranitidine		NaCl 0.9%    WFI	Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity, e.g. haloperidol, metoclopramide and levomepromazine	2





## Syringe Driver Drug Compatibilities – Guide to Practice 2013

DRUG	COMPATIBILITY	DILUENT	COMMENT	REFERENCE
Haloperidol, Midazolam	A,B	NaCl 0.9%		8
Haloperidol, Midazolam, Morphine Sulfate	A,B	NaCl 0.9%		1
Haloperidol, Midazolam, Octreotide		NaCl 0.9%		1
Haloperidol, Midazolam, Oxycodone	B	NaCl 0.9%	WFI	1
Haloperidol, Morphine Sulfate		NaCl 0.9%	WFI	1,2
Haloperidol, Morphine Sulfate, Octreotide		NaCl 0.9%	WFI	1
Haloperidol, Morphine Tartrate		NaCl 0.9%		1
Haloperidol, Octreotide		NaCl 0.9%		2
Haloperidol, Octreotide, Oxycodone		NaCl 0.9%	WFI	2
Haloperidol, Ondansetron		NaCl 0.9%		2
Haloperidol, Oxycodone	A,B	NaCl 0.9%	WFI	1,6
<b>Hydromorphone</b>		NaCl 0.9%	WFI	1
Hydromorphone, Hyoscine Butylbromide		NaCl 0.9%		2
Hydromorphone, Hyoscine Butylbromide, Levomepromazine	C	NaCl 0.9%		2
Hydromorphone, Hyoscine Butylbromide, Midazolam		NaCl 0.9%		2
Hydromorphone, Ketamine	A,B,C	NaCl 0.9%		1
Hydromorphone, Ketamine, Levomepromazine	C	NaCl 0.9%		2





## Syringe Driver Drug Compatibilities – Guide to Practice 2013

DRUG	COMPATIBILITY	DILUENT	COMMENT	REFERENCE
Hydromorphone, Ketamine, Midazolam	C	NaCl 0.9%		1
Hydromorphone, Levomepromazine	C	NaCl 0.9%    WFI		2
Hydromorphone, Levomepromazine, Metoclopramide	C	NaCl 0.9%	Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity eg haloperidol, metoclopramide and levomepromazine	2
Hydromorphone, Levomepromazine, Midazolam	C	NaCl 0.9%    WFI		2
Hydromorphone, Levomepromazine, Ranitidine	C	NaCl 0.9%	Combination appears to be physically incompatible with increasing levomepromazine concentration. Consider using 2 syringe drivers	1,2
Hydromorphone, Metoclopramide		NaCl 0.9%    WFI		2
Hydromorphone, Metoclopramide, Midazolam		NaCl 0.9%    WFI		1,2
Hydromorphone, Metoclopramide, Octreotide		NaCl 0.9%		2
Hydromorphone, Metoclopramide, Ondansetron		NaCl 0.9%		2
Hydromorphone, Midazolam	A,B	NaCl 0.9%		1
Hydromorphone, Octreotide, Ondansetron		NaCl 0.9%		2
Hydromorphone, Ondansetron	A,B	NaCl 0.9%		1
<b>Hyoscine Butylbromide (Hyoscine BBr)</b>		NaCl 0.9%    WFI		1
Hyoscine BBr, Ketamine, Levomepromazine	C	NaCl 0.9%		2
Hyoscine BBr, Levomepromazine, Morphine Sulfate	A,B,C	NaCl 0.9%		1
Hyoscine BBr, Levomepromazine, Octreotide	C	NaCl 0.9%    WFI		2





## Syringe Driver Drug Compatibilities – Guide to Practice 2013

DRUG	COMPATIBILITY	DILUENT	COMMENT	REFERENCE
Hyoscine BBr, Levomepromazine, Ondansetron	C	NaCl 0.9%		2
Hyoscine BBr, Levomepromazine, Oxycodone	A,B,C	NaCl 0.9%		1
Hyoscine BBr, Methadone, Ranitidine	C	NaCl 0.9%		2
Hyoscine BBr, Metoclopramide	B	WFI	The prokinetic effect of metoclopramide may be inhibited by hyoscine butylbromide	2
Hyoscine BBr, Metoclopramide, Midazolam	B	NaCl 0.9%	The prokinetic effect of metoclopramide may be inhibited by hyoscine butylbromide	1
Hyoscine BBr, Midazolam	B	NaCl 0.9%		1
Hyoscine BBr, Midazolam, Morphine Sulfate		NaCl 0.9%	WFI	1,2
Hyoscine BBr, Midazolam, Oxycodone		NaCl 0.9%	WFI	1,2
Hyoscine BBr, Morphine Sulfate, Octreotide		NaCl 0.9%	WFI	1,2
Hyoscine BBr, Morphine Sulfate, Ondansetron		NaCl 0.9%		1
Hyoscine BBr, Oxycodone	A,B	NaCl 0.9%	WFI	1,6
<b>Hyoscine Hydrobromide (Hyoscine HBr)</b>		NaCl 0.9%	WFI	1
Hyoscine HBr, Ketorolac, Ranitidine		NaCl 0.9%		1
Hyoscine HBr, Levomepromazine, Morphine Sulfate	C	NaCl 0.9%		1
Hyoscine HBr, Levomepromazine, Oxycodone	A,B,C	NaCl 0.9%		1
Hyoscine HBr, Midazolam	A,B	NaCl 0.9%		8







## Syringe Driver Drug Compatibilities – Guide to Practice 2013

DRUG	COMPATIBILITY	DILUENT	COMMENT	REFERENCE
Hyoscine HBr, Midazolam, Morphine Sulfate		NaCl 0.9%    WFI		1,2
Hyoscine HBr, Midazolam, Morphine Tartrate		NaCl 0.9%		1
Hyoscine HBr, Midazolam, Oxycodone		NaCl 0.9%    WFI		2
Hyoscine HBr, Morphine Sulfate, Octreotide		NaCl 0.9%		1
Hyoscine HBr, Oxycodone	A,B	NaCl 0.9%    WFI		1,6
<b>Ketamine</b>	C	NaCl 0.9%		1
Ketamine, Levomepromazine	C	NaCl 0.9%		1
Ketamine, Levomepromazine, Metoclopramide	C	NaCl 0.9%	Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity eg haloperidol, metoclopramide and levomepromazine	2
Ketamine, Levomepromazine, Oxycodone	C	NaCl 0.9%		2
Ketamine, Methadone	C	NaCl 0.9%    WFI		2
Ketamine, Metoclopramide	C	NaCl 0.9%		2
Ketamine, Midazolam	C	NaCl 0.9%		1
Ketamine, Midazolam, Morphine Sulfate	C	NaCl 0.9%    WFI		2
Ketamine, Midazolam, Oxycodone	C	NaCl 0.9%    WFI		2
Ketamine, Morphine Sulfate	A,B,C	NaCl 0.9%		9
Ketamine, Oxycodone	A,B,C	NaCl 0.9%    WFI		6





## Syringe Driver Drug Compatibilities – Guide to Practice 2013

DRUG	COMPATIBILITY	DILUENT	COMMENT	REFERENCE	
<b>Ketorolac</b>		NaCl 0.9%	Dilute maximally with NaCl 0.9% Seek specialist advice	1	
Ketorolac, Methadone	A,B,C	NaCl 0.9%		10	
Ketorolac, Oxycodone	B	NaCl 0.9%		1	
Ketorolac, Oxycodone, Ranitidine	B	NaCl 0.9%	WFI	1	
Ketorolac, Ranitidine		NaCl 0.9%		1	
<b>Levomepromazine</b>	C	NaCl 0.9%	WFI	Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity, e.g. haloperidol, metoclopramide and levomepromazine	1
Levomepromazine, Methadone, Midazolam	C	NaCl 0.9%		2	
Levomepromazine, Metoclopramide	C	NaCl 0.9%	WFI	Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity, e.g. haloperidol, metoclopramide and levomepromazine	2
Levomepromazine, Metoclopramide, Morphine Sulfate	A,B,C	NaCl 0.9%		Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity, e.g. haloperidol, metoclopramide and levomepromazine	1
Levomepromazine, Metoclopramide, Octreotide	C	NaCl 0.9%	WFI	Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity, e.g. haloperidol, metoclopramide and levomepromazine	1
Levomepromazine, Metoclopramide, Oxycodone	A,B,C	NaCl 0.9%		Increased risk of extrapyramidal adverse effects when combining drugs with dopamine activity, e.g. haloperidol, metoclopramide and levomepromazine	1
Levomepromazine, Midazolam	C	NaCl 0.9%	WFI		1
Levomepromazine, Midazolam, Morphine Sulfate	A,B,C	NaCl 0.9%			1
Levomepromazine, Midazolam, Octreotide	C	NaCl 0.9%			1
Levomepromazine, Midazolam, Oxycodone	C	NaCl 0.9%	WFI		2





## Syringe Driver Drug Compatibilities – Guide to Practice 2013

DRUG	COMPATIBILITY	DILUENT	COMMENT	REFERENCE
Levomepromazine, Morphine Sulfate	C	NaCl 0.9%    WFI		1,2
Levomepromazine, Morphine Sulfate, Octreotide	C	NaCl 0.9%    WFI		2
Levomepromazine, Octreotide	C	NaCl 0.9%    WFI		1,2
Levomepromazine, Octreotide, Ondansetron	C	NaCl 0.9%		1
Levomepromazine, Octreotide, Oxycodone	B,C	NaCl 0.9%    WFI		1
Levomepromazine, Ondansetron	C	NaCl 0.9%    WFI		1,2
Levomepromazine, Ondansetron, Oxycodone	C	NaCl 0.9%		2
Levomepromazine, Oxycodone	A,B,C	NaCl 0.9%    WFI		1,6
Levomepromazine, Ranitidine	C	NaCl 0.9%    WFI	Combination appears to be physically incompatible with increasing levomepromazine concentration	1
<b>Lignocaine</b>		NaCl 0.9%		5
<b>Methadone</b>	C	NaCl 0.9%    WFI		1
Methadone, Midazolam	C	NaCl 0.9%    WFI		1,2
Methadone Octreotide Ranitidine	C	NaCl 0.9%		2
<b>Metoclopramide</b>		NaCl 0.9%    WFI		1
Metoclopramide, Midazolam	B	NaCl 0.9%		1
Metoclopramide, Midazolam, Morphine Sulfate	A,B	NaCl 0.9%		1





## Syringe Driver Drug Compatibilities – Guide to Practice 2013

DRUG	COMPATIBILITY	DILUENT	COMMENT	REFERENCE
Metoclopramide, Midazolam, Oxycodone	A,B	NaCl 0.9%		1
Metoclopramide, Midazolam, Ranitidine		NaCl 0.9%		2
Metoclopramide, Morphine Sulfate		NaCl 0.9%	WFI	1,2
Metoclopramide, Morphine Sulfate, Octreotide		NaCl 0.9%		2
Metoclopramide, Morphine Sulfate, Ranitidine		NaCl 0.9%		2
Metoclopramide, Morphine Sulfate, Ondansetron		NaCl 0.9%		1
Metoclopramide, Morphine Tartrate		NaCl 0.9%		1
Metoclopramide, Octreotide		NaCl 0.9%	WFI	1,2
Metoclopramide, Octreotide, Oxycodone		NaCl 0.9%	WFI	1,2
Metoclopramide, Ondansetron	A,B	NaCl 0.9%		1
Metoclopramide, Ondansetron, Oxycodone		NaCl 0.9%		1
Metoclopramide, Oxycodone	A,B	NaCl 0.9%	WFI	1,6
Metoclopramide, Ranitidine		NaCl 0.9%		2
<b>Midazolam</b>		NaCl 0.9%	WFI	1
Midazolam, Morphine Sulfate		NaCl 0.9%	WFI	1,2
Midazolam, Morphine Sulfate, Octreotide		NaCl 0.9%		1









## Syringe Driver Drug Compatibilities – Guide to Practice 2013

DRUG	COMPATIBILITY	DILUENT		COMMENT	REFERENCE
Midazolam, Morphine Sulfate, Ondansetron		NaCl 0.9%			2
Midazolam, Octreotide, Oxycodone		NaCl 0.9%			1
Midazolam, Olanzapine		NaCl 0.9%			1
Midazolam, Ondansetron	A,B	NaCl 0.9%			1
Midazolam, Ondansetron, Oxycodone		NaCl 0.9%			1
Midazolam, Oxycodone	A,B	NaCl 0.9%	WFI		1,6
<b>Morphine Sulfate</b>		NaCl 0.9%	WFI		1
Morphine Sulfate, Octreotide		NaCl 0.9%	WFI		1,2
Morphine Sulfate, Ondansetron	A,B	NaCl 0.9%			1
<b>Octreotide</b>		NaCl 0.9%	WFI		1
Octreotide, Ondansetron	B	NaCl 0.9%	WFI		1
Octreotide, Ondansetron, Oxycodone	B	NaCl 0.9%	WFI		1
Octreotide, Oxycodone	B	NaCl 0.9%	WFI		1,2
<b>Olanzapine</b>		NaCl 0.9%	WFI	Initial dilution of powder with WFI prior to further dilution	1
<b>Ondansetron</b>		NaCl 0.9%	WFI		1
Ondansetron, Oxycodone		NaCl 0.9%	WFI		1,2





## Syringe Driver Drug Compatibilities – Guide to Practice 2013

DRUG	COMPATIBILITY	DILUENT		COMMENT	REFERENCE
<b>Oxycodone</b>		NaCl 0.9%	WFI		1
Oxycodone, Ranitidine		NaCl 0.9%	WFI		1
<b>Ranitidine</b>		NaCl 0.9%	WFI		1
<b>Sufentanil</b>		NaCl 0.9%		Little compatibility data is available. Incompatibility has not been observed in combination with clonazepam, ketamine, methadone, levomepromazine, metoclopramide, midazolam and octreotide	5,11



### REFERENCES

1. Dickman A, Schneider J. The Syringe Driver. Continuous subcutaneous infusions in palliative care. 3rd ed. Oxford: Oxford University Press; 2011
2. Syringe Driver Survey Database available at [www.palliativedrugs.org](http://www.palliativedrugs.org) Accessed April-May 2013
3. Guidelines for Subcutaneous Infusion Device Management in Palliative Care – second edition 2010 available at [www.health.qld.gov.au/cpcrc](http://www.health.qld.gov.au/cpcrc) Accessed April - May 2013
4. Twycross R, Wilcock A. Palliative Care Formulary. 4<sup>th</sup> ed. Nottingham. Palliativedrugs.com Ltd; 2011
5. Trissel L. Handbook on Injectable Drugs. 17th ed. Bethesda, MD. American Society of Health-System Pharmacists. 2013 Accessed online April - May 2013
6. Hines S, Pleasance S. Compatibility of an injectable high strength oxycodone formulation with typical diluents, syringes, tubings, infusion bags and drugs for potential co-administration. Eur J Hosp Pharm Pract. 2009; 15: 32-38
7. Ambados, F. Brealey J. Compatibility of ketamine hydrochloride and fentanyl citrate in polypropylene syringes. Am J Health Syst Pharm 2004; 61:1438-1439
8. Gomez MAM, Arenas VJ, Sanjuan MM, Hernandez MJM, Almenar CB, Torress VJ. Stability Studies of Binary Mixtures of Haloperidol and/or Midazolam with Other Drugs for Parenteral Administration. J Palliat Med. 2007; 10:1306-1311
9. Schmid R, Koren G, Klein J. The stability of a ketamine-morphine solution. Anesth Analg. 2002;94:898-900
10. Destro M, Ottolini L, Vicentini L, Boschetti S. Physical compatibility of binary and ternary mixtures of morphine and methadone with other drugs for parenteral administration in palliative care. Support Care Cancer. 2012; 20:2501–2509
11. White C, Hardy J, Boyd A, Hall A. Subcutaneous sufentanil for palliative care patients in a hospital setting. Palliat Med. 2008;22:89-90

### **Acknowledgements**

#### **EMRPCC Syringe Driver Review 2013**

Project officer: Ms S Scholes, *BPharm Grad Cert Health (Palliative Care) MSHP AACPA*

#### **EMRPCC Clinical Group representatives (2013)**

*Eastern Health*: Director of Palliative Care, Clinical Nurse Consultant, Social Worker

*Eastern Palliative Care Assoc. Inc*: Palliative Care Physician, Clinical Nurse Consultant, Family Support Consultant

*St Vincent's Hospital – Melbourne*: Palliative Care Clinical Nurse Consultant, Occupational Therapist

*Royal District Nursing Service*: Clinical Nurse Specialist (Palliative Care)

*EMRPCC*: Consortium Manager

#### **Special Acknowledgments:**

J McCarthy Eastern Health (Wantirna Health) Palliative Care Pharmacist

Also the original EMRPCC clinical group of 2008 and all contributors to the initial *EMRPCC Syringe Driver Medication Compatibilities- Practice Guidelines (October2008)*

And the 2011 EMRPCC clinical group who revised the document as *EMRPCC Syringe Driver Drug Compatibilities- Practice Guidelines 2011*